EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimal direct oral anticoagulant for upper gastrointestinal endoscopic submucosal dissection

Yoshitaka Ono, Waku Hatta iD, Kunio Tarasawa, Yohei Ogata, Hiroko Abe, Isao Sato, Yutaka Hatayama, Masahiro Saito, Xiaoyi Jin, Kaname Uno, Tomoyuki Koike, Akira Imatani und 4 weitere

Journal of Gastroenterology · 2025

DOI: 10.1007/s00535-024-02171-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology, 2025. Verfasst von Yoshitaka Ono und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-Machi, Aoba-Ku, Sendai, 980-8574, Japan. Hauptthemen laut MEDLINE: Endoscopic Mucosal Resection, Rivaroxaban, Pyridones, Pyrazoles. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Promotion Administration, Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The patients taking direct oral anticoagulants (DOACs) are at high risk for developing ischemic stroke and delayed bleeding in upper gastrointestinal endoscopic submucosal dissection (ESD). We aimed to identify the optimal DOAC based on both adverse events in upper gastrointestinal ESD.

Methods

A retrospective population-based cohort study was conducted using the Diagnosis Procedure Combination database in Japan. We included patients on a DOAC undergoing upper gastrointestinal ESD between 2012 and 2021. The primary outcomes were ischemic stroke occurring after upper gastrointestinal ESD and delayed bleeding in gastroduodenal and esophageal ESD. Inverse probability weightings were applied to balance the four DOAC groups (dabigatran, rivaroxaban, apixaban, and edoxaban), and logistic regression analyses were performed to compare the outcomes.

Results

We analyzed 9729 patients on a DOAC undergoing upper gastrointestinal ESD. Ischemic stroke developed after upper gastrointestinal ESD in 1.4%, 0.7%, 0.6%, and 0.8% of patients taking dabigatran, rivaroxaban, apixaban, and edoxaban, respectively, after weighting. Rivaroxaban and apixaban showed significantly lower risk of ischemic stroke compared with dabigatran (odds ratio, 0.15 and 0.12, respectively) in standard doses. The delayed bleeding developed after gastroduodenal ESD in 7.6%, 14.6%, 19.2%, and 17.3% of patients taking each DOAC, respectively, with the lowest risk in dabigatran, followed by rivaroxaban. A similar pattern was observed in delayed bleeding in esophageal ESD (3.2%, 5.4%, 7.5%, and 5.5% in each DOAC), but with no significant results.

Conclusions

Rivaroxaban might be an optimal DOAC for upper gastrointestinal ESD showing a lower risk for both ischemic stroke and delayed bleeding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endoscopic Mucosal ResectionRivaroxabanPyridonesPyrazolesHumansMaleAgedFemaleRetrospective StudiesMiddle AgedDabigatranAged, 80 and overJapanPyridinesFactor Xa InhibitorsGastrointestinal HemorrhageIschemic StrokeAdministration, OralThiazolesAnticoagulants

Stichwörter der Autor:innen

Delayed bleedingDirect oral anticoagulantEndoscopic submucosal dissectionIschemic strokeRivaroxaban

Substanzen

RivaroxabanPyridonesPyrazolesapixabanDabigatranedoxabanPyridinesFactor Xa InhibitorsThiazolesAnticoagulants

Autor:innen und Institutionen

  • Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-Machi, Aoba-Ku, Sendai, 980-8574, Japan.
  • Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-Machi, Aoba-Ku, Sendai, 980-8574, Japan. waku-style@festa.ocn.ne.jp.
  • Department of Health Administration and Policy, Tohoku University Graduate School of Medicine, 2-1 Seiryo-Machi, Aoba-Ku, Sendai, 980-8575, Japan.
  • Department of Health Policy and Informatics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, S1560/S1568 M&D Tower 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8519, Japan.

ORCID-Profile: Waku Hatta

Förderung

  • Health Promotion Administration, Ministry of Health and Welfare

Zitieren

APA

Ono, Y., Hatta, W., Tarasawa, K., Ogata, Y., Abe, H., Sato, I., Hatayama, Y., Saito, M., Jin, X., Uno, K., Koike, T., Imatani, A., Hamada, S., Fujimori, K., Fushimi, K., & Masamune, A. (2025). Optimal direct oral anticoagulant for upper gastrointestinal endoscopic submucosal dissection. Journal of Gastroenterology. https://doi.org/10.1007/s00535-024-02171-2

Vancouver

Ono Y, Hatta W, Tarasawa K, Ogata Y, Abe H, Sato I, et al. Optimal direct oral anticoagulant for upper gastrointestinal endoscopic submucosal dissection. Journal of Gastroenterology. 2025. doi:10.1007/s00535-024-02171-2

BibTeX
@article{Ono2025,
  author = {Ono, Yoshitaka and Hatta, Waku and Tarasawa, Kunio and Ogata, Yohei and Abe, Hiroko and Sato, Isao and Hatayama, Yutaka and Saito, Masahiro and Jin, Xiaoyi and Uno, Kaname and Koike, Tomoyuki and Imatani, Akira and Hamada, Shin and Fujimori, Kenji and Fushimi, Kiyohide and Masamune, Atsushi},
  title = {Optimal direct oral anticoagulant for upper gastrointestinal endoscopic submucosal dissection},
  journal = {Journal of Gastroenterology},
  year = {2025},
  doi = {10.1007/s00535-024-02171-2}
}
Kostenlos starten →